{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:24:02Z","timestamp":1780788242065,"version":"3.54.1"},"reference-count":42,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T00:00:00Z","timestamp":1618790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Myeloma Canada","award":["1111"],"award-info":[{"award-number":["1111"]}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","award":["1111"],"award-info":[{"award-number":["1111"]}],"id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The prognosis of multiple myeloma (MM), an incurable B-cell malignancy, has significantly improved through the introduction of novel therapeutic modalities. Myeloma prognosis is essentially determined by cytogenetics, both at diagnosis and at disease progression. However, for a large cohort of patients, cytogenetic analysis is not always available. In addition, myeloma patients with favorable cytogenetics can display an aggressive clinical course. Therefore, it is necessary to develop additional prognostic and predictive markers for this disease to allow for patient risk stratification and personalized clinical decision-making. Genomic instability is a prominent characteristic in MM, and we have previously shown that the three-dimensional (3D) nuclear organization of telomeres is a marker of both genomic instability and genetic heterogeneity in myeloma. In this study, we compared in a longitudinal prospective study blindly the 3D telomeric profiles from bone marrow samples of 214 initially treatment-na\u00efve patients with either monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), or MM, with a minimum follow-up of 5 years. Here, we report distinctive 3D telomeric profiles correlating with disease aggressiveness and patient response to treatment in MM patients, and also distinctive 3D telomeric profiles for disease progression in smoldering multiple myeloma patients. In particular, lower average intensity (telomere length, below 13,500 arbitrary units) and increased number of telomere aggregates are associated with shorter survival and could be used as a prognostic factor to identify high-risk SMM and MM patients.<\/jats:p>","DOI":"10.3390\/cancers13081969","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T21:59:49Z","timestamp":1618869589000},"page":"1969","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Telomere Architecture Correlates with Aggressiveness in Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"given":"Aline","family":"Rangel-Pozzo","sequence":"first","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pak","family":"Yu","sequence":"additional","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadhana","family":"LaL","sequence":"additional","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Asbaghi","sequence":"additional","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7452-5756","authenticated-orcid":false,"given":"Luiza","family":"Sisdelli","sequence":"additional","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"},{"name":"Genetic Bases of Thyroid Tumors Laboratory, Division of Genetics, Department of Morphology and Genetics, Universidade Federal de S\u00e3o Paulo, S\u00e3o Paulo 04082-001, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pille","family":"Tammur","sequence":"additional","affiliation":[{"name":"Department of Clinical Genetics, United Laboratories, Tartu University Hospital, 50406 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9539-3131","authenticated-orcid":false,"given":"Anu","family":"Tamm","sequence":"additional","affiliation":[{"name":"United Laboratories, Tartu University Hospital, 50406 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Punab","sequence":"additional","affiliation":[{"name":"Department of Haematology and Bone Marrow Transplantation, Clinic of Haematology and Oncology, Tartu University Hospital, 50406 Tartu, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludger","family":"Klewes","sequence":"additional","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherif","family":"Louis","sequence":"additional","affiliation":[{"name":"Telo Genomics Corp, Toronto, ON M5G1L7, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7909-7866","authenticated-orcid":false,"given":"Hans","family":"Knecht","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Medicine, Jewish General Hospital, McGill University, Montr\u00e9al, QC H3T 1E2, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adebayo","family":"Olujohungbe","sequence":"additional","affiliation":[{"name":"Haematology, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5797-2201","authenticated-orcid":false,"given":"Sabine","family":"Mai","sequence":"additional","affiliation":[{"name":"Cell Biology, Research Institute of Oncology and Hematology, University of Manitoba, CancerCare Manitoba, Winnipeg, MB R3C 2B1, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,4,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V91.1.3","article-title":"Multiple myeloma: Increasing evidence for a multistep transformation process","volume":"91","author":"Hallek","year":"1998","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood-2016-09-692954","article-title":"MGUS to myeloma: A mysterious gammopathy of underexplored significance","volume":"128","author":"Dhodapkar","year":"2016","journal-title":"Blood"},{"key":"ref_3","unstructured":"Albagoush, S.A., and Azevedo, A.M. (2018). Cancer, Multiple Myeloma, StatPearls Publishing."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1053\/j.seminoncol.2019.03.001","article-title":"State of the science in smoldering myeloma: Should we be treating in the clinic?","volume":"46","author":"Hill","year":"2019","journal-title":"Semin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/943096","article-title":"Mechanisms and Clinical Applications of Genome Instability in Multiple Myeloma","volume":"2015","author":"Cagnetta","year":"2015","journal-title":"Biomed Res. Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fonc.2018.00355","article-title":"Multiple myeloma exemplifies a model of cancer based on tissue disruption as the initiator event","volume":"8","author":"Capp","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/17474086.2018.1537776","article-title":"Prognostic factors for multiple myeloma in the era of novel therapies","volume":"11","author":"Ziogas","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.1517\/14712598.2013.814637","article-title":"Genomic instability in multiple myeloma: Mechanisms and therapeutic implications","volume":"13","author":"Neri","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/gcc.22689","article-title":"From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes","volume":"58","author":"Gadji","year":"2019","journal-title":"Genes Chromosom. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1101\/gad.1346005","article-title":"Shelterin: The protein complex that shapes and safeguards human telomeres","volume":"19","year":"2005","journal-title":"Genes Dev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Mender, I., and Shay, J. (2015). Telomere Dysfunction Induced Foci (TIF) Analysis. Bio Protoc., 5.","DOI":"10.21769\/BioProtoc.1656"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bjh.14643","article-title":"Telomere length is a critical determinant for survival in multiple myeloma","volume":"178","author":"Hyatt","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/jcb.22501","article-title":"Initiation of telomere-mediated chromosomal rearrangements in cancer","volume":"109","author":"Mai","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yu, P.L.I., Wang, R.R., Johnston, G., Wang, Y., Tammur, P., Tamm, A., and Mai, S. (2019). Distinct Nuclear Organization of Telomeresand Centromeres in Monoclonal Gammopathyof Undetermined Significance and Multiple Myeloma. Cells, 8.","DOI":"10.3390\/cells8070723"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"749-IN36","DOI":"10.1593\/tlo.13613","article-title":"Three-dimensional Nuclear Telomere Organization in Multiple Myeloma","volume":"6","author":"Klewes","year":"2013","journal-title":"Transl. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1046\/j.1365-2818.2001.00949.x","article-title":"Generalized approach for accelerated maximum likelihood based image restoration applied to three-dimensional fluorescence microscopy","volume":"204","author":"Schaefer","year":"2002","journal-title":"J. Microsc."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cyto.a.20159","article-title":"Characterizing the three-dimensional organization of telomeres","volume":"67","author":"Vermolen","year":"2005","journal-title":"Cytom. Part A"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2011.09022.x","article-title":"Telomere dysfunction and its role in haematological cancer","volume":"156","author":"Jones","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wark, L., Quon, H., Ong, A., Drachenberg, D., Rangel-Pozzo, A., and Mai, S. (2019). Long-Term Dynamics of Three Dimensional Telomere Profiles in Circulating Tumor Cells in High-Risk Prostate Cancer Patients Undergoing Androgen-Deprivation and Radiation Therapy. Cancers, 11.","DOI":"10.3390\/cancers11081165"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Drachenberg, D., Awe, J.A., Pozzo, A.R., Saranchuk, J., and Mai, S. (2019). Advancing risk assessment of intermediate risk prostate cancer patients. Cancers, 11.","DOI":"10.3390\/cancers11060855"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Corr\u00eaa de Souza, D., Schmid-Braz, A.T., de Azambuja, A.P., Ferraz-Aguiar, T., Borgonovo, T., and Mai, S. (2019). 3D Telomere Structure Analysis to DetectGenomic Instability and Cytogenetic Evolutionin Myelodysplastic Syndromes. Cells, 8.","DOI":"10.3390\/cells8040304"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/jcb.20760","article-title":"The significance of telomeric aggregates in the interphase nuclei of tumor cells","volume":"97","author":"Mai","year":"2006","journal-title":"J. Cell. Biochem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Freitas, M.O., Gartner, J., Rangel-Pozzo, A., and Mai, S. (2020). Genomic instability in circulating tumor cells. Cancers, 12.","DOI":"10.3390\/cancers12103001"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Sisdelli, L., Cordioli, M.I.V., Vaisman, F., Caria, P., Mai, S., and Cerutti, J.M. (2020). Genetic landscape of papillary thyroid carcinoma and nuclear architecture: An overview comparing pediatric and adult populations. Cancers, 12.","DOI":"10.3390\/cancers12113146"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rangel-Pozzo, A., Booth, S., Yu, P.L.I., Singh, M., Selivanova, G., and Mai, S. (2020). p53 CRISPR Deletion Affects DNA Structure and Nuclear Architecture. J. Clin. Med., 9.","DOI":"10.3390\/jcm9020598"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4982","DOI":"10.1182\/blood-2002-11-3451","article-title":"Telomerase and telomere length in multiple myeloma: Correlations with disease heterogeneity, cytogenetic status, and overall survival","volume":"101","author":"Wu","year":"2003","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1034\/j.1600-0609.2003.00157.x","article-title":"Telomere shortening in patients with plasma cell disorders","volume":"71","author":"Cottliar","year":"2003","journal-title":"Eur. J. Haematol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.trecan.2020.05.006","article-title":"Genomic Instability in Multiple Myeloma","volume":"6","author":"Alagpulinsa","year":"2020","journal-title":"Trends Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3389\/fgene.2020.00228","article-title":"Drug Targeting of Genomic Instability in Multiple Myeloma","volume":"11","author":"Beksac","year":"2020","journal-title":"Front. Genet."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Schrank, Z., Khan, N., Osude, C., Singh, S., Miller, R., Merrick, C., Mabel, A., Kuckovic, A., and Puri, N. (2018). Oligonucleotides Targeting Telomeres and Telomerase in Cancer. Molecules, 23.","DOI":"10.3390\/molecules23092267"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1038\/leu.2008.81","article-title":"Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo","volume":"22","author":"Shammas","year":"2008","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrc1691","article-title":"The concept of synthetic lethality in the context of anticancer therapy","volume":"5","author":"Kaelin","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1182\/blood-2011-06-363911","article-title":"Bortezomib-induced \u201cBRCAness\u201d sensitizes multiple myeloma cells to PARP inhibitors","volume":"118","author":"Neri","year":"2011","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3324\/haematol.2018.215210","article-title":"ATR addiction in multiple myeloma: Synthetic lethal approaches exploiting established therapies","volume":"105","author":"Botrugno","year":"2019","journal-title":"Haematologica"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1038\/onc.2015.464","article-title":"Targeting glutamine metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to venetoclax","volume":"35","author":"Bajpai","year":"2016","journal-title":"Oncogene"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1969\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:49:57Z","timestamp":1760161797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/8\/1969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,19]]},"references-count":42,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,4]]}},"alternative-id":["cancers13081969"],"URL":"https:\/\/doi.org\/10.3390\/cancers13081969","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,19]]}}}